Charles River Associates Expands Life Sciences Practice with Appointment of Two Seasoned Industry Leaders Charles River Associates (NASDAQ: CRAI), a globally recognized leader in economic, financial, and management consulting, has…
Genmab Appoints Dr. Katja Nielsen as General Manager for Germany, Strengthening European Commercial Expansion Genmab A/S (Nasdaq Copenhagen: GMAB), a global biotechnology leader in antibody-based medicines for cancer and other…
Roche’s Susvimo Shows Durable Vision Preservation Over Five Years with Twice-Yearly Treatment in Neovascular AMD Roche has released compelling new long-term data highlighting the extended efficacy, safety, and durability of…
Spine BioPharma Releases Phase 3 Data for SB-01 in Chronic Low Back Pain: Trial Misses Primary Endpoint Amid Strong Safety and Subgroup Efficacy Signals Spine BioPharma, Inc., a clinical-stage biopharmaceutical…
United Therapeutics Launches $1 Billion Accelerated Share Repurchase Initiative, Underscoring Confidence in Long-Term Growth and Shareholder Value In a bold affirmation of its robust financial health, strategic vision, and shareholder-centric…
Arrowhead’s Subsidiary Visirna Transfers Greater China Rights to Plozasiran to Sanofi in Strategic $395 Million Deal Amid Regulatory Milestone in Hypertriglyceridemia In a move poised to reshape the therapeutic landscape…
European Commission Greenlights AUCATZYL®: AGC Biologics Marks 10th Regulatory Approval with Autolus’ CAR-T Therapy AGC Biologics, a global contract development and manufacturing organization (CDMO) specializing in biologics and advanced therapies,…
Altasciences and VoxCell BioInnovation Forge Strategic Partnership to Revolutionize Preclinical Drug Development with 3D Bioprinted Human Tissue Models In a move poised to reshape the landscape of early-stage drug development,…
BeOne Medicines Achieves Key Regulatory Milestone as EMA Grants PRIME Designation to BTK Degrader BGB-16673 for Waldenstrom’s Macroglobulinemia BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), an emerging global…
Bayer Raises Full-Year Outlook on Strong Pharma Performance, While Setting Aside €1.7 Billion for U.S. Litigation Risks Ahead of its scheduled second-quarter 2025 earnings release on August 6, Bayer AG…
Merck Completes €665 Million Divestment of Surface Solutions Business to GNMI, Marking Strategic Realignment Toward Innovation-Focused Growth In a decisive move underscoring its strategic emphasis on core technological and scientific…
Actio Biosciences Receives FDA IND Clearance and Fast Track Designation for ABS-1230 in KCNT1-Related Epilepsy, Marking Major Advancement in Pediatric Precision Medicine Actio Biosciences, a clinical-stage biotechnology company pioneering novel…